Biotechnology

CANBRIDGE-B

CANBRIDGE-B released FY2025 9 Months Earnings on March 30, 2026 (BJT) with actual revenue of HKD 39.25 M and EPS of HKD 0.1

CANBRIDGE-B released FY2025 Q3 earnings on March 30, 2026 (BJT) with actual revenue of HKD 15.16 M and EPS of HKD -0.0508

CANBRIDGE-B released FY2025 earnings on March 30 During-Market (BJT), actual revenue HKD 54.63 M (forecast HKD 161.74 M), actual EPS HKD 0.0327 (forecast HKD -0.826)

CANBRIDGE-B released FY2025 Q4 earnings on March 30 During-Market (BJT), actual revenue HKD 15.42 M, actual EPS HKD -0.0438

CANBRIDGE-B to Release FY2025 Earnings on March 30 During-Market (BJT), Forecast Revenue HKD 161.74 M, EPS HKD -0.826

Nichi Xia Cheng B-Type Private Plc Issues 84,033,600 Shares to Wuxi Biologics HealthCare Venture

Nordic Nanovector Raises Nearly HK$200 Million Through Rights Issue to WuXi Biologics

BiochemChina's CAN 103 Included in Commercial Insurance Catalog and Officially Enters Clinical Use

BioMedicines Biologics Concludes Share Subscription Underwriting Settlement for HK$22,591,400

Concord Pharmaceutical Issues 9,996,200 Shares to 3 Subscribers

Concord Pharmaceutical's Shareholders Deposit Shares into 浦银国际证券

Canbridge Pharmaceuticals Products Pass Initial Review and Reach Agreement With Byoncare

CANBRIDGE-B released FY2025 Q1 earnings on August 31 (BJT), actual revenue HKD 11.91 M, actual EPS HKD 0.0749

ConchChem-B Interim Report: Revenue Decreased by 50.33%

CANBRIDGE-B released FY2025 Semi-Annual earnings on August 31 During-Market (BJT), actual revenue HKD 24.09 M, actual EPS HKD 0.1509

CANBRIDGE-B released FY2025 Q2 earnings on August 31 During-Market (BJT), actual revenue HKD 12.18 M, actual EPS HKD 0.0763

ConchChem-B Issues 74,971,500 New Shares at HKD1.34 Per Share

CANBRIDGE-B FY2025 Semi-Annual Earnings Release on August 29, 2025 (BJT)

Nordic Nanovector Raising 100 Million HKD Through Share Placement

Canbridge Pharmaceuticals' Gorinerin Prescribes First Prescription for Gaucher Disease

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

01228

CANBRIDGE announced its 2025 annual performance, with revenue of 50 million yuan (same below), a year-on-year decrease of 41.2%. It turned a profit of 14.82 million yuan, compared to a loss of 443 million yuan in the same period last year; earnings per share were 0.03 yuan. No dividend was declared

AASTOCKS

"Performance" CANBRIDGE turned a profit, earning 14.82 million RMB for the year, and will not distribute dividends

159316

159506

520690

CANbridge Pharmaceuticals Inc. has completed a share subscription, issuing 84,033,613 new shares at HK$2.38 each, increasing its total issued share capital to 595,443,347 shares. This transaction raises the new subscriber's stake to 16.26%, while existing major shareholder Baheal's holding is diluted to 16.32%. The deal reshapes the shareholder structure, potentially strengthening the company's financial position but diluting existing shareholders' interests. The latest analyst rating for CANbridge stock is a Buy with a price target of HK$3.00.

Tip Ranks

E Fund Hang Seng SCHK Innovative Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Huaan Hang Seng Biotech ETF

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Tianhong CNI BIOMEDICINE ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

CANbridge Completes HK$2.38 New Share Subscription, Reshaping Shareholder Base

560600

159837

588130

CANbridge Pharmaceuticals Inc. has announced a subscription agreement to issue 84,033,613 new shares at HK$2.38 each, raising approximately HK$199 million. The shares will be sold to a Hong Kong limited partnership owned by WuXi Biologics, at a discount to market prices. Proceeds will be used for working capital, R&D, and settling trade payables. The transaction is subject to regulatory approval and reflects ongoing support from WuXi Biologics. The latest analyst rating for CANbridge stock is a Buy with a target price of HK$3.00.

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

WUXI BIO

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

WuXi Biologics

CANbridge to Raise HK$199 Million via Discounted Share Subscription Backed by WuXi Biologics Unit

CANBRIDGE-B rose 15.58%; 3SBio fell 3.69%, with a transaction volume of HKD 576 million; CanSino Biologics fell 3.86%, with a transaction volume of HKD 526 million; Innovent Biologics fell 2.87%, with a transaction volume of HKD 403 million; BeiGene fell 1.27%, with a market value of HKD 310.6 billion

HK Stock Alerts

Hong Kong stock movement: CANBRIDGE-B rose by 15.58%, with clear capital flow, market sentiment triggered volatility attention

02575

03681

百奥赛图-B

02126

08622

On October 27th, the Hong Kong stock market saw significant gains in the pharmaceuticals and biotechnology sector. XUANZHUBIO-B rose nearly 19%, CANBRIDGE-B increased over 14%, SINOMAB BIO-B climbed over 11%, BAIOO SAI TU-B and HUAKANG BIOMED both surged over 9%, and JW THERAP-B rose over 8%

Zhitong

XUANZHUBIO-B

SINOMAB BIO-B

JW THERAP-B

JOYZYME GROUP

The Hong Kong stock market's pharmaceutical and biotechnology sector leads in gains

According to the announcement from CANBRIDGE-B, the conditions specified in the subscription agreement have been met, and the delivery of the subscription matter was implemented on September 26, 2025, in accordance with the terms and conditions of the subscription agreement. On the delivery date, the company allocated and issued a total of 9.996 million subscription shares to the subscribers at a subscription price of HKD 2.26 per share, as stated in the announcement. The total amount raised from the subscription matter is HKD 22.5914 million

CANBRIDGE-B completed the issuance of 9.996 million shares, raising approximately HKD 22.5914 million

CANBRIDGE-B rose over 8% in the morning, and as of the time of publication, it was up 8.16%, trading at HKD 3.05, with a transaction volume of HKD 20.5877 million. In terms of news, CANBRIDGE-B announced that on September 15, 2025, the company plans to issue a total of 9.9962 million subscription shares to three subscribers (Qin Shen, Huang Xiaoting, and Wusong Capital Limited). The subscription price for each share is HKD 2.26, which represents a discount of approximately 19.86% compared to the closing price of HKD 2.82 on September 15. The announcement stated that the total amount raised from the subscription will be HKD 22.5914 million, with the net proceeds estimated to be approximately HKD 22.0914 million. The company intends to use the net proceeds from the subscription for research and development expenses of existing product lines and for the group's daily operations

Understanding the Market | CANBRIDGE-B rose over 8% in the morning, plans to issue subscription shares at a discount of approximately 19.86% to raise funds for existing product line R&D expenses, etc

CANBRIDGE-B plans to issue 9.9962 million shares to 3 subscribers on September 15, 2025, with a subscription price of HKD 2.26 per share, representing a discount of approximately 19.86% to the closing price. This subscription is expected to raise HKD 22.5914 million, with a net amount of approximately HKD 22.0914 million, primarily for research and development expenses and daily operations

CANBRIDGE-B plans to issue 9,996,200 shares at a discount of approximately 19.86%, raising about HKD 22,091,400 net

CANBRIDGE-B announced that it will issue a total of 9.9961 million new shares to three independent third parties, equivalent to an enlarged share capital of 1.96%; the price per share is HKD 2.26, representing a discount of 19.86% compared to the last trading day (15th). The total amount raised is HKD 22.59 million, with a net amount of HKD 22.09 million, intended for research and development expenses for existing product lines and daily operations

CANBRIDGE-B is issuing new shares at a discount of 19.86%, raising a net amount of 22.09 million yuan

CANBRIDGE-B(01228.HK)